Skip to main content
Clinical Trials/NCT05926895
NCT05926895
Completed
Not Applicable

Investigation of the Effect of Central Sensitization on Steroid Injection Response in Patients With Shoulder Pain Secondary to Rotator Cuff Lesion

Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey1 site in 1 country44 target enrollmentJune 2, 2023

Overview

Phase
Not Applicable
Intervention
Injection of 1 CC Betamethasone Dipropionate + Betamethasone Sodium Phosphate (Diprospan) and 4 cc 2% Prilocaine (Priloc)mixture into the subacromial space
Conditions
Central Sensitisation
Sponsor
Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey
Enrollment
44
Locations
1
Primary Endpoint
Shoulder range of motion
Status
Completed
Last Updated
7 months ago

Overview

Brief Summary

The goal of this clinical trial is to learn whether pretreatment central sensitization presence affect shoulder steroid injection resuls in patients with rotator cuff pathology.

The main questions it aims to answer are:

  1. Is central sensitization associated with decreased treatment response?
  2. Do the clinical features of patients with central sensitization differ from those of those without? Participants will be applied a shoulder injection and the treatment response will be monitored.

Detailed Description

Shoulder pain is one of the most common musculoskeletal complaints and its prevalence varies between 7-26%. One of the most common sources of pain in these patients is subacromial impingement syndrome leading to rotator cuff pathology. In patients with shoulder pain, one of the factors associated with the persistence of pain in different etiologies, especially subacromial impingement syndrome, is reported as central sensitization (CS). CS can be summarized as an increase in the response of neurons located in the central nervous system to sub-threshold stimuli. In a meta-analysis of patients with shoulder pain, a decrease in pressure pain threshold was found in 29-77% of patients, and CS in 11-24%. There is increasing data showing that CS negatively affects response to different treatments, including surgery and injections. One of the most frequently used treatments in subacromial impingement syndrome is subacromial/intra-articular shoulder injection. Although various factors have been identified in the prediction of shoulder injection results, the effect of pain sensitization on these procedures is unknown. In this study, it is planned to investigate the effect of the presence and severity of pretreatment central sensitization on the results of the shoulder injection in patients with a rotator cuff lesion or subacromial impingement.

Registry
clinicaltrials.gov
Start Date
June 2, 2023
End Date
December 30, 2024
Last Updated
7 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Rotator cuff pathology confirmed clinically and radiologically (USG/MRI)
  • Failure to respond to medical/physical treatment
  • Agree to participate in the study

Exclusion Criteria

  • Shoulder trauma and history of previous shoulder surgery
  • History of injection to the painful shoulder in the last 3 months
  • Use of centrally acting drugs (antidepressants, pregabalin, gabapentin and myorelaxant etc.)
  • History of active cancer, systemic inflammatory disease, and infection
  • Pregnancy

Arms & Interventions

Patients with subacromial impingement syndrome (central sensitization positive)

Subacromial steroid injection While the patient is in a sitting position the subacromial space and the rotator cuff will be evaluated with the sonosite-m turbo ultrasonography device linear probe. The area where the rotator cuff and subacromial bursa are most prominent will be determined under the deltoid muscle. The injection site is first covered with povidone iodine and then with 80% alcohol solution will be wiped to provide antisepsis. The subacromial bursa between the deltoid muscle and the rotator cuff will be advanced from lateral to medial with an inplane approach with a 21 g 38 mm needle under the guidance of ultrasonography. Bleeding after making sure that the needle tip is in the bursa by checking, 1 cc betamethasone dipropionate + betamethasone sodium phosphate and 4 cc 2% prilocaine mixture will be injected, showing that it is evenly distributed in the bursa.

Intervention: Injection of 1 CC Betamethasone Dipropionate + Betamethasone Sodium Phosphate (Diprospan) and 4 cc 2% Prilocaine (Priloc)mixture into the subacromial space

Patients with subacromial impingement syndrome (central sensitization negative)

Subacromial steroid injection While the patient is in a sitting position the subacromial space and the rotator cuff will be evaluated with the sonosite-m turbo ultrasonography device linear probe. The area where the rotator cuff and subacromial bursa are most prominent will be determined under the deltoid muscle. The injection site is first covered with povidone iodine and then with 80% alcohol solution will be wiped to provide antisepsis. The subacromial bursa between the deltoid muscle and the rotator cuff will be advanced from lateral to medial with an inplane approach with a 21 g 38 mm needle under the guidance of ultrasonography. Bleeding after making sure that the needle tip is in the bursa by checking, 1 cc betamethasone dipropionate + betamethasone sodium phosphate and 4 cc 2% prilocaine mixture will be injected, showing that it is evenly distributed in the bursa.

Intervention: Injection of 1 CC Betamethasone Dipropionate + Betamethasone Sodium Phosphate (Diprospan) and 4 cc 2% Prilocaine (Priloc)mixture into the subacromial space

Outcomes

Primary Outcomes

Shoulder range of motion

Time Frame: 3 months

Goniometric measurement of flexion, extension, abduction, adduction and internal and external rotation angles of the shoulder complex

Visual analog scale

Time Frame: 3 months

The visual analog scale (VAS) is a validated subjective measure for pain, scored in the 0-10 range (0:no pain; 10: worst pain).

Secondary Outcomes

  • QuickDASH(3 months)
  • SF-36 (Short form-36)(3 months)
  • Hospital anxiety and depression scale (HADS)(3 month)
  • hand grip strength(3 months)
  • Pressure pain threshold (PPT)(3 months)

Study Sites (1)

Loading locations...

Similar Trials